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Tumor cellEndothelin-1 induced signaling is characterized by an early induction of a nuclear factor-kappa B
p65/mitogen-activated phosphokinase p38 transcription complex via its A-receptor versus a late induction
via diacylglycerol, and protein kinase C. A possible interaction between these two pathways and a potential
function for protein kinase C in this context has not previously been elucidated. Here we report that in Caki-1
tumor cells, protein kinase Cα is a part of the transcription complex.With importinα4 andα5 as chaperones,
the transcription complex transmigrates into the nucleus. Protein kinase Cα blocks the nuclear release of pri-
microRNA 15a by direct binding shown by electrophoretic mobility shift assay and Duolink immune histology.
The expression levels of miRNA 15a can be further manipulated by transfection of si-protein kinase C α, or an
expression vector containing protein kinase C α or miRNA 15. The miRNA 15a regulation by protein kinase C α
is detectable in different malignant human tumor cell lines (renal cell carcinoma, breast carcinoma, and
melanoma). Furthermore, all three cell lines harbor both endothelin receptors (ETAR/ETBR). Speciﬁc blockage
of each receptor leads to major reduction of miRNA 15a expression due to increased nuclear protein kinase C
α translocation. We conclude that the nuclear binding of pri-microRNA 15a is a novel function of protein
kinase C α, which plays an important role in endothelin-1 mediated signaling. Since several endothelin-
sensitive, malignant tumor cell lines harbor this regulation, it could indicate a more general role in tumor
biology.: +49 221 478 6360.
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Endothelin-1 mediated signal transduction via an inﬂammatory
signal transduction cascade involves the pleiotropic nuclear factor
kappa B (NF-κB) family of dimeric transcription factors. Recently, we
have shown that mitogen-activated protein kinase p38α (MAPK p38α)
associates with NF-κB p65 after ET-1 stimulation to form a functional
transcription complex (TC) in the cytoplasm [1].
MAPK p38α is a member of the mammalian ortholog of the yeast
HOG kinase that participates in a signaling cascade controlling cellular
responses to cytokines and stress. Besides the p38α isoform
(MAPK14), three others have been identiﬁed: p38β (MAPK11),
p38γ (MAPK12 or ERK6), and p38δ (MAPK13 or SAPK4). p38α has
been shown to participate in various cellular processes, including:
inﬂammation, growth, differentiation, death, post-transcriptionalregulation, senescence, and tumor suppression [2]. In the literature,
the function of the full length p38 has been mainly regarded as a
donor of phosphate groups [3–5] in different cell lines.
Our group demonstrated (2008, [1]) the direct interaction
between the MAPK p38 and the NF-κB pathway. We found that
p38α forms a transcription complex (TC) with NF-κB p65 already in
the cytoplasm, migrating as a complex into the nucleus via Importin
α4 and α5, where it participates in the expression of different genes
with NF-κB target-sites such as VCAM-1, IL-6 and fractalkine [6]. The
induction of this TC followed a bimodal course, being highly active at 6
and 24 h after ET-1 stimulation. While the early induction has been
proven to be endothelin receptor A (ETAR) speciﬁc [1], the late
induction involves the diacylglycerol–protein kinase C mediated
pathway (PKC) [6,7]. This suggests a potential direct link between
PKC activation and TC.
PKC has been identiﬁed as an important signaling pathway in awide
variety of cell types [8–10]. This serine/threonine kinase has been
associated with signal transduction pathways resulting in cell differen-
tiation, division, contraction, and secretion [9,10]. At present, 13
members of the PKC family of protein kinases have been identiﬁed.
On the basis of structural similarities in their regulatory domain and the
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have been classiﬁed into three groups: the classical PKCs (cPKCs), the
novel PKCs (nPKCs), and the atypical PKCs (aPKCs) [8]. The classical
group of PKCs include PKC α, PKC β (βI and βII), and PKC γ. The C1
region of these isoenzymes contains 2 cysteine-rich zinc-ﬁnger motifs
separated by 8 to 15 residues. These two zinc ﬁnger-like motifs are
thought to synergistically provide for the ability to bind to and to be
activated by diacylglycerol (DAG) [9]. As potential interactive partners
for TC, the classicalmembers of PKC appear to be of primary interest due
to their regulation by DAG. However, the function of the different PKC
isoforms is still largely unknown.
In this context, Cohen et al. [11] recently described that the α
isoform of PKC is associated with the down-regulation of miRNA 15a
in head and neck squamous cell carcinoma, identifying this miRNA as
a potential inhibitor of DNA synthesis and PKC α as a regulator of
tumor cell growth in squamous cell carcinoma. However, the
potential mechanism of this inverse relationship was not shown.
MicroRNAs (miRNAs) are short, non-coding RNAs that can play
important roles in cell function and development by targeting mRNA
sequences of protein-coding transcripts, resulting in either mRNA
cleavage or repression of productive translation in the cytoplasm
[12–15]. MiRNA 15a has been described as a tumor suppressor,
promoting apoptosis, and inhibiting cell proliferation by targeting
multiple oncogenes [16]. Downregulation of miRNA 15a and 16-1 has
consequently been reported in lymphoproliferative disorders, mul-
tiple myeloma [17], and prostate cancer [18].
In this paper, we identify the mechanism of the inverse
relationship between PKC α and miRNA 15a, and its connection
with the TC.We have shown that PKCα forms a transcription complex
with NF-κB p65 and MAPK p38, transmigrating into the nucleus,
where it binds to pri-microRNA15, preventing its nuclear release.
Endothelin-1 stimulation decreases PKC α levels, leading to an
increase in miRNA 15a levels. This regulation can be observed in
different malignant tumor cell lines, pointing to a more general role in
biology.
2. Materials and methods
All reagents used were commercially available at Sigma-Aldrich,
except, when otherwise speciﬁed.
Sequence of miRNA 15a including seed sequence (Gene bank
MIMAT 0000068): 5′-GUG UUU GGU AAU ACA CGA CGA U-3′.
2.1. Blobﬁnder
For quantiﬁcation of the Eurogentec experiment the free com-
mercial software, Blobﬁnder, was used according to the manufac-
turer's recommendation (http://www.cb.uu.se/~amin/BlobFinder/).
To quantify differences not readily visible bymicroscopic inspection,
this program can help by analyzing the images based on a single cell
analysis. This analysis simulates a cytoplasm and assigns each signal to a
particular cell. In the output, every cell has a value representing the
number of signals in that particular cell compartment.
2.2. Cell culture
Caki-1 (renal cell carcinoma), SKmel 28 (melanoma), and MCF-7
(breast carcinoma) cells were cultured as previously described [1,6].
2.3. Cell treatments
Cells were treated with endothelin-1 (50 nM) for different time
points. Before treatments the cells were serum starved for 24 h.
The endothelin A and B receptor blockage was performed as
previously described [1,6].2.4. Densitometry
For densitometric analysis the ImageJ programwas used according to
the protocols. Brieﬂy, ameasuring areawasplaced around the individual
signal and the intensity measured. Then, the same area was used to
measure the background signal (noise) of the respective Western blot.
The two values were subtracted from each other. The same procedure
was followed for all signals and their respectiveWestern blot “noise.” To
determine the net signal of each band, the corresponding calculated
value of the ß-actin loading was regarded as 100%, and the proportional
value of each of the protein signals (p65, p38, PKC) was calculated.2.5. Immunoprecipitation
For immunoprecipitation, either a p38 or PKC α agarose
conjugated antibody (Santa Cruz) was used. The assay was performed
according to the Santa Cruz protocol with a 1000 μg total cellular
protein. The ﬁnal washing stepwas done 4×with PBS and the samples
were diluted in 15 μl 2× electrophoresis sample buffer. After a boiling
step of 4 min, the samples were centrifuged and used forWestern blot
analysis.2.6. miRNA isolation
miRNA from cell culture experiments was isolated with the
PureLink miRNA isolation kit from Invitrogen according to the
manufacturer's protocol. miRNA was quantiﬁed using the NanoDrop
technology.2.7. Non-radioactive electrophoretic mobility shift assay (EMSA)
Nuclear extracts were isolated from endothelin treated and
untreated cells according to the manufacturer's protocol (Nuclear
extraction kit, Active motif). Protein content was assayed with the
Bradfordprotein assay (Bio-Rad)withBSA as standard. Double stranded
pri-miRNA 15a oligonucleotides (5′-TGTGGATTTTGAAAAGG-3′) were
commercially synthesized (Invitrogen) and the forward strand was
labeled with Alexa 647. pri-miRNA 15a binding reactions were
conducted in 200 mM TRIS–HCL pH 7.6, 50 mM MgCl2, 0.1 mM EDTA
and 10 mMDTT. To prepare theDNA for annealing, the oligonucleotides
(1 pmol each) were incubated at 70 ° for exactly 10 min and a further
30 min at room temperature. For the protein/RNA binding reaction, 5 μg
of protein were added to the samples and incubated on ice for 30 min.
The reaction was analyzed by electrophoresis in a non-denaturation 6%
polyacrylamide gel in 1×TBE buffer.
For supershift EMSAs, a PKCα antibody (Santa Cruz) was used. As
negative control, 100× more concentrated non-labeled, “cold” pri-
miRNA 15a was incubated with 5 μg of protein and added to the Alexa
labeled sample. As binding and negative control, a mutated pri-miRNA
15a (Alexa 647-GTGTTCGGGGTCCCCTT, Invitrogen) oligo was used as
well. All EMSAs were performed in triplicates and visualized with a
ﬂuorescence reader (FLA-3000, Fujiﬁlm).2.8. Nuclear extract and cytoplasmic isolation
Nuclear and cytoplasmic extracts were isolated from treated cells
and controls according to the manufacturer's protocol (nuclear
extraction kit, Active motif). Protein content was assayed with the
Bradford protein assay (Bio-Rad) with bovine serum albumin as
standard.
For nuclear miRNA isolation, the nuclear fraction was mixed with
300 μl binding buffer and preparation was done according to the
PureLink RNA mini Kit (Invitrogen).
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The nuclear extracts from Caki-1 cells were treated for 24 h with
ET-1. Nuclear extract was isolated (as described previously) and
150 μg of this extract was incubated with a PKC α speciﬁc agarose
conjugated antibody (described previously in immunoprecipitation).
After the antibody binding procedure, the sample was washed 2×
with 1× PBS. After the ﬁnal wash, the total RNAwas isolated according
to the Qiagen protocol. RNA was quantiﬁed, RT-PCR was carried out
and PCR with primers speciﬁc for pri-miRNA 15a detection was
performed.2.10. PKC α binding of pri-miRNA 15a—in-situ detection by Duolink Kit
1×105 cells grown on Labtecs were washed with PBS and incubated
with Tfx™-50 reagent according to the manufacturer's protocol
(Promega). The pri-miRNA 15a oligonucleotide sequence was labeled
with biotin at the 5′ end (biotin-TGTGGATTTTGAAAAGG, Invitrogen).
The optimal Tfx™-50:biotin-pri-miRNA 15a ratio was determined to be
6:6. The mixture was incubated in DMEM at room temperature for
15 min. In between, DMEM was removed, the cells were washed with
PBS and treated with the Tfx™-50:biotin-pri-miRNA 15a and ET-1
50 nM for 24 h (as used before). For ﬁxation, a methanol:acetone
(1:1, v/v) dilution was used. After removal of DMEM, slides were
washed in PBS, air dried, and incubated in ice-cold methanol:
acetone (1:1, v/v) for 90 s. After the ﬁxation procedure, the Duolink
kit was used according to the manual. The cells were incubated with
a blocking solution in a pre-heated humidity chamber at 37 °C for
30 min, followed by primary antibody incubation for 2 h at room
temperature. Incubation with the PLA probes for 1.5 h at 37 °C
followed, and the detection protocol according to the recommended
time points was applied.
After completing the ﬁnal step, slides were mounted in Invitrogen
ﬂuorescence mounting medium with DAPI (Invitrogen) for nuclear
staining. The Leica Aristoplan microscope with Discus software was
used for visualization.2.11. RNA isolation
RNA and miRNA were isolated with the RNeasy and micro RNeasy
kit from Qiagen according to the manufacturer's protocol. RNA was
quantiﬁed using the NanoDrop technology.2.12. RT-PCR
The cDNA was obtained from 500 ng RNA using random primers
and SuperScript III reverse transcriptase according to the manufac-
turer's protocol (Invitrogen). In order to be in the semi-quantitative
range, the amount of cDNA was previously determined by titration
and the number of PCR cycles was standardized. The PCR reactions
were performed in a ﬁnal volume of 25 μl. For PCR reaction, 1 μl of the
RT-PCR product was always used and mixed with RedTaq Ready Mix
(Sigma) or Platinum Taq polymerase (Invitrogen) according to the
manufacturer's protocol. The PCR reactions were performed with 35
cycles consisting of 0.5–1 min at 94 °C, 1 min at 55 °C annealing
temperature, 1 min at 72 °C with a ﬁnal extension between 5 and
10 min at 72 °C.
Primers: ß-actin, forward: TTG GCA ATG AGC
GGT TCC GCT G, reverse: TAC ACG TGT TTG CGG ATG TCC AC,
temperature 53 °C, 35 cycles; PKC α, forward: ATG GCT GAC GTT TTC
CCG G, reverse: AGG TGG GCT GCT TGA AGA, temperature 55 °C, 35
cycles; pri-miRNA 15a, forward: CTA AGG CAC TGC TGA CAT TGC T,
reverse: GTA GCA GCA CAT AAT GGT TTG TGG, temperature 56 °C, 35
cycles.For analysis and binding speciﬁcity control of the PCR a 2.5%
agarose gels or 10% polyacrylamide gels were performed and were
run in 1× TAE buffer.2.13. Isolation and detection of miR-15a
miR-15a was isolated from Caki-1 cells using miRNeasy mini Kit
(Qiagen). The mirVana qRT-PCR Primer Set for miR-15a was used
according to manufacturer's instruction. Primer set for 5 s rRNA was
used to normalize among different samples.2.14. Quantitative real-time PCR (qRT-PCR)
Either 1 μl of the above mentioned cDNA or 250 ng of the genomic
DNA were used for real-time PCR analysis. The experimental settings
were as described previously [6].
Real-time PCR was conducted on M×3000 (Stratagene) starting at
95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s and 1 min at
55 °C. For quantitative analysis, β-actin was measured using the
QuantiTect SYBR Green PCR kit (Qiagen). All sampleswere normalized
to ß-actin as reference gene. All experiments were done in triplicate.
Relative ﬂuorescence was calculated using the ΔΔCT method as
outlined in User Bulletin 2 (PE Applied Biosystems). The statistical
signiﬁcance of qRT-PCR values at different time points was assessed
by Student's paired t test.2.15. Sanger sequencing
The gel-extracted PCR product from the PKC α agarose antibody
immunoprecipitation was prepared for Sanger sequencing according
to the BigDye® protocol. The product was sequenced by the Cologne
Center for Genomics and analyzed with the FinchTV v. 1.4.0.2.16. siRNA transfection
The siRNA transfection of PKC α was done according to the Santa
Cruz protocol. Best results were received with a concentration of 6 μl
siRNA duplex and 6 μl transfection reagent. After transfection, the
cells were incubated in DMEM and incubated for 42 h. The RNA,
nuclear and cytoplasmic extracts were isolated as described. To proof
transfection efﬁciency, a PCR with special Santa Cruz primers was
performed according to the protocols provided. siRNA-A was used as
control according to the Santa Cruz protocol.2.17. Statistics
All experiments were performed in triplicates.
Mean and standard deviation were calculated. Differences
between matched groups were analyzed by ttest for paired
variables. Values of pb0.05 were considered statistically signiﬁcant.
Statistical signiﬁcance of PKC α or miRNA 15a values observed at
different time points after ET-1 stimulation was assessed by one-way
analysis of variance [19,20], followed by pre-planned multiple
pairwise comparisons, utilizing a critical t value calculated by the
Bonferroni method [21,22], as modiﬁed for ΔΔCT qRT-PCR values [23].
To evaluate the results of PKC α expression in different
experimental groups (control, ET-1 24 h, ETAR block 24 h, ETBR
24 h) two-away analysis of variance (ANOVA) was used, a procedure
that yields numerical values for the ET-1 and ETR block effect and an
interaction term. Relevant differences between values between any 2
groups were assessed for statistical signiﬁcance by multiple pairwise
comparisons and modiﬁed t-statistics.
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1×106 cells were grown on 6-well plates until reaching conﬂu-
ence of 60–80%. For transfection of 1.5 μg plasmid, Lipofectamine
(Invitrogen) was used according to the manufacturer's protocol.
Plasmids without insert were used as transfection controls. The
expression plasmids (PKCα and miRNA 15a) were commercially
provided by Addgene (Cambridge, MA, USA).
After either transient or siRNA transfection the cells were
stimulated with ET-1 for 24 h.
2.19. Western blot analysis
Western blot analysis was performed as described in [1,6]. For the
analysis of the PKC α, p65, p38 (α/β) and β-actin antibodies from
Santa Cruz were used and tested for speciﬁcity with Santa Cruz
designed peptides.
3. Results
3.1. The α isoform of PKC becomes part of the complex between NF-κB
p65 und MAPK p38
To study the interaction between PKC and the TC built by NF-κB
p65 and MAPK p38, known PKC isoforms were analyzed by Western
blot in cytoplasmic extracts from untreated and endothelin-1
treated Caki-1 cells. Among the different isoforms present, predom-
inantly the classic subtypes alpha, beta 1, and gamma are found to
be reduced after ET-1 treatment (Fig. 1A). Twenty-four hours after
ET-1 treatment, PKC μ and ι are down-regulated as well, while the
changes in the levels of the other isoforms are statistically
insigniﬁcant (as shown by densitometry Fig. 1A). The other PKC
isoforms δ, η, θ, ζ, λ were not detectable (data not shown).
To study the time course of the relationship between the three
potential factors of the TC, Caki-1 cells were ET-1 treated and nuclear
extracts were analyzed for p65, p38 and PKC α at 1, 3, 6, 12, 24 h
(Fig. 1B). ß-actin levels show equal loading of protein. PKC α, p65 and
p38 are present at all time points investigated in the cytoplasm and in
the nucleus (except for cytoplasmic p38 at 24 h).
By immunoprecipitation with a PKC α antibody, as capture
conjugated to agarose beads, both factors p65 and p38 are detectable
as binding partners (Fig. 1C). The TC is already formed in the
cytoplasm and is detectable in the nucleus (Fig. 1C).
3.2. Nuclear transport of the TC including PKC α involves importins
In our previous studies we demonstrated that the TC is migrating
as a complex into the nucleus. The complex is attached to so-called
importins, to be chaperoned through the nuclear pores. The subtype
α4 andα5 are particularly involved. To showwhether this interaction
is also true for the TC enlarged by the attachment of PKC α, we
analyzed the immunoprecipitated PKC α complex from Fig. 1B, for
members of the importin family (Fig. 2). Only importin α4 and α5,
predominantly at 12 and 24 h after ET-1 stimulation, could be
demonstrated. Other members, especially the beta component,
could not be detected.Fig. 1. PKC α is part of the NF-κB transcription complex. (A) Western Blot and correspond
untreated Caki-1 cells. As loading control β-actin was used. Densitometry shows reduction o
PKC ε, ν, γ (B) PKC α, p65 and p38 expression in cytoplasmic versus nuclear extracts after 50
analysis. Densitometry reveals that the relationship of PKC α expression levels in the cyto
corresponding densitometry shows increased nuclear localization for NF-кB p65, MAPK p38
(C) Immunopreciptiation assay, using a PKCα agarose conjugated antibody as capture. The an
the speciﬁcity of the PKCα antibodywas demonstrated. The lower panel presents the same e
the cytoplasm and presence in the nucleus.3.3. Inverse relationship between levels of PKC α and miRNA 15a
Since reports in the literature describe an inverse relationship
between PKC α and miRNA 15a, we analyzed this setting in Caki-1
cells using mRNA, miRNA and protein extracts (Fig. 3). We ﬁrst
studied whether this relationship by analyzing the RNA levels of
expression of both factors at 3, 6, 12 and 24 h after ET-1 stimulation in
Caki-1 cells by qRT-PCR. At 3 h, with PKC α levels being low, miRNA
15a was present in higher amounts. At 6 and 12 h the expression of
both factors is decreased. This relation begins to change at 24 h after
ET-1 stimulation (Fig. 3A). When the PKC α values obtained at 3
different time points are compared by one-way analysis of variance
(ANOVA), signiﬁcant differences between the time points is evi-
denced by a calculated F ratio of 246.65 (pb0.0001). Multiple pairwise
comparisons indicate that the difference between values seen at 3, 6,
and 12 versus 24 h are statistically signiﬁcant (t=22.14/21.65/22.78,
respectively), while all other comparisons (3 and 6 h, 3 and 12 h, 6
and 12 h) are not signiﬁcant (t=0.49/0.64/1.13; calculated by
Bonferroni's multiple comparison test).
When themiRNA 15a values obtained at 3 different time points are
compared by one-way analysis of variance, signiﬁcant differences
between the time points are evidenced by a calculated F ratio of 3279
(pb0.0001). Multiple pairwise comparisons indicate that the differ-
ence between values seen at 3 versus 6 h (t=84.79), 3 versus 12 h
(t=86.84), 3 and 24 h (t=54.10), 6 and 24 h (t=30.69) and 12 and
24 h (t=32.74) are statistically signiﬁcant, while the comparison
between 6 and 12 h is not signiﬁcant (t=0.2; calculated by
Bonferroni's multiple comparison test).
To demonstrate whether the levels of both factors could be
regulated, transfection studies with expression vectors for PKC α,
siRNAagainst PKCα,miRNA15aandwithanon-relevant siRNA(control
siRNA) were performed and analyzed by qRT-PCR and Western blot
analysis (Fig. 3C). As qRT-PCR levels, shown in Fig. 3B's top panel, the
miRNA 15a expression after PKCα transfection compared to siRNA PKC
α transfection is reduced by ~50%. An expression vector for miRNA 15a
upregulates its levels. In order to control the procedure of siRNA
transfection, cells were transfected in a separate experiment, with
control siRNA showing a statistic signiﬁcant induction for miRNA 15a
after siRNA PKC α transfection (pb0.05).
In the lower panel, the PKC α mRNA levels are depicted. The
transfection with an expression vector for PKC α leads to high PKC α
levels. Transfection of siRNA PKC α reduces the levels to those of
control siRNA transfection. An expression vector for miRNA 15a is
associated with a moderate increase of PKC α levels.
A Western blot was performed (Fig. 3C, top panel) in order to
exclude post transcriptional modiﬁcations and to demonstrate control
PKCα protein levels. The densitometric analysis in Fig. 3C lower panel
reveals that control levels equal those after control siRNA transfection.
These levels are clearly modiﬁed in a reverse relationship by
manipulating PKC α and miRNA 15a.3.4. PKC α is able to bind directly to pri-miRNA 15a in the nucleus,
preventing miRNA release into the cytoplasm
Thus, we studied whether this potential interaction could be proven
by two different methods. Using nuclear extracts of ET-1 treated oring densitometry from cyptoplasmic extracts (20 μg) of treated (24 h 50 nM ET-1) or
f PKC isoforms after 24 h ET-1 treatment (mean±SD). pb0.05 for PKC α, β1, μ, ι. N.S. for
nM ET-1 treatment over time in Caki-1 cells. A 20 μg protein was used for Western blot
plasm is reversed in the nucleus (pb0.05). β-Actin was used as loading control. The
and PKC α at 12 and 24 h after ET-1 treatment. All experiments were done in triplicates.
alysis by SDS–Page allows the detection of NF-кB p65 andMAPK p38. In the right panel,
xperimental setting for cytoplasmic and nuclear extracts, demonstrating TC formation in
1797M. von Brandenstein et al. / Biochimica et Biophysica Acta 1813 (2011) 1793–1802untreated Caki-1 cells and a non-radioactively labeled oligonucleotide
speciﬁc for the pri-miRNA 15a sequence by EMSA, a signal is detectable
(Fig. 4A). This signal is found in untreated and ET-1 treated Caki-1 cells.0
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binding signal has almost completely vanished.
To visualize and demonstrate the direct interaction between PKCα
and miRNA 15a in a different assay, the Duolink immune histology
methodwas employed (Fig. 4B), representing proximity ligation assay
technology. Caki-1 cells, treated with ET-1 for 24 h or untreated, were
transfected with biotinylated pri-miRNA 15a and the interaction
between pri-miRNA 15a and PKC α in the nucleus was detected via a
Duolink kit. Only in the case of a speciﬁc closeness would it be possible
to detect dot-like signals. Such ﬂuorescence signals are detectable in
the nuclei of Caki-1 cells being slightly stronger in control conditions
than at 24 h after ET-1 stimulation, analyzed with the Blobﬁnder
program.3.5. Direct interaction between PKC α and pri-miRNA 15a
To demonstrate the interaction between pri-miRNA 15a and PKC α,
primerswere designedwhichwould speciﬁcally amplify a stretch of pri-
miRNA 15a with the expected binding site of PKC α (upper panel) as
depicted in Fig. 5 (left lower panel).
The right lower panel represents the result of agarose gel electropho-
resis showing the expected size of the ampliﬁcatewhichwas obtained by
PCR after an immunoprecipitation using PKC α agarose beads. To control
the speciﬁcity of the PCR product, the nucleotide sequence of the
ampliﬁcate was analyzed by Sanger sequencing (data not shown).
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Fig. 5.Direct interaction of PKCα and pri-miRNA 15a.The ﬁgure has three parts: top panel displays the predicated PKCα /pri-miRNA15a binding sequence including the subsequence
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literature, this loop represents the entire pre-miRNA15a, while the ﬂanking sequences belong to the pri-miRNA15a [31]. The experiment shown in the right lower panel used nuclear
extract followed by an immunoprecipation with the previously used PKCα speciﬁc antibody (speciﬁcity already shown in 1C). After the binding reaction between the nuclear extract
and the PKC α antibody, the RNA was isolated and a PCR with the primer pair shown in the left lower panel (the 3' primer speciﬁc for pri-miRNA) was performed. With this primer
set, the generated ampliﬁcate represents a pri-miRNA15a sequence. After agarose gel electrophoresis showing the expected size of the ampliﬁcate, the band was isolated and the
nucleotide sequence determined by the Sanger method, proving it to be pri-miRNA15a.
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formation and miRNA 15a expression
Since the action of endothelin is transmitted by speciﬁc receptors
(ETAR and ETBR), their presence and potential activation by ET-1
were analyzed in different cell lines (Caki-1, SKmel 28 and MCF-7)
(Fig. 6A). Both receptors were detectable in all three cell lines.
Compared to untreated cells, a statistically signiﬁcant increase in
receptor expression could only be detected in Caki-1 and MCF-7 cells
after ET-1 treatment for ETBR, but not for ETAR (pb0.05).
To demonstrate complex formation in SKmel 28 andMCF-7 cells in
analogy to Caki-1 cells an immunoprecipitation with PKC α agarose
conjugated antibody used as capture was performed. The Western
blot in Fig. 6B reveals the presence of the expected binding partners,
p65 and p38.
Subsequent analysis of miRNA expression shows a relative
increase of miRNA 15a in ET-1 treated cells by qRT-PCR (Fig. 6C).3.7. Inﬂuence of the endothelin receptors on miRNA 15a expression
PKCα expression was analyzed byWestern blot using cytoplasmic
versus nuclear extracts in ET-1 treated or untreated Caki-1 cells. In
addition, the ETA or the ETB receptor was blocked 1 h prior to ET-1
treatment. The results were analyzed by densitometry and two-way
analysis of variance (ANOVA) (Fig. 7A).
In the cytoplasm (top line), PKC α levels increase in all treated
subgroups versus controls, with highly signiﬁcant F values for the
treatment effect (pb0.001). In the nucleus (bottom line), PKCα levels
decrease after ET-1 treatment with or without ETA block versus
controls, which is reﬂected by the signiﬁcant levels attained by the F
values, calculated for the interaction term (pb0.001). In contrast,
nuclear PKC α levels after ETB block are not signiﬁcantly different
from controls.
Subsequently, analyzing the miRNA 15a levels in the respective
treatment groups yielded high relative ﬂuorescence units (RFU)
after ET-1 by qRT-PCR. In contrast, blocking either the ETA or ETB
receptor caused strong reduction of miRNA 15a expression
(pb0.001) (Fig. 7B).4. Discussion
Potential roles of the PKC signaling pathway have been elusive
despite the discovery of its intricate system of particular isoforms
being expressed in speciﬁc cell types. While Cohen et al. (2009, [11])
have described that PKC α can counter regulate levels of miRNA 15a
in squamous cell carcinoma, the actual mode of interaction between
PKC alpha and miRNA 15a has not been identiﬁed. From our data, we
propose a pathway as depicted in Fig. 7 8. We show in our study that
the PKC α leads to decreased cytoplasmic levels of miRNA 15a by
direct PKC α protein/pri-miRNA 15a interaction in the nucleus
(Fig. 8). This is demonstrated by three different experiments: I. an
EMSA with a pri-miRNA 15a oligonucleotide and a subsequent
supershift analysis using speciﬁc antibodies against PKC α (Fig. 4A).
As the EMSA with a mutated oligonucleotide shows, this occurs via a
speciﬁc recognition site, after PKC α has co-migrated into the
nucleus as part of the NF-κB/MAPK (Fig. 1B) complex. II. By Duolink
immune histology (which is a proximity ligation assay technology in
living cells), the interaction between PKC α and pri-miRNA 15a
results in a nuclear complex is visualized (Fig. 4B). III. By nuclear
extract followed by immunoprecipitation with a PKC α speciﬁc
antibody, the bound RNA was isolated and used in a PCR with
speciﬁc pri-miRNA 15a primers. The PCR product was extracted from
the agarose gel and the identity of the pri-miRNA 15a conﬁrmed by
Sanger sequencing.
Under control conditions, high nuclear PKC α levels maintain the
uninduced state of a cell by preventing the release of mature miRNA
15a, which explains the increased signals of the PKCα/pri-miRNA 15a
complex in untreated cells (Fig. 4B).
However, when nuclear PKC α protein levels drop after 24 h ET-1
stimulation in Caki-1 cells (Fig. 7A, lower panel), the protein levels of
PKC α become insufﬁcient to completely bind pri-miRNA 15a
(Fig. 4B). pri-miRNA 15a is subsequently processed to pre-miRNA,
escaping into the cytoplasm, where it is made into miRNA 15 (Fig. 7B).
The regulation of miRNA 15a expression is not restricted to a
speciﬁc tumor cell line, namely Caki-1, but can also be observed in
ET-1 inducible cell lines from different tumor entities (Fig. 6C) in
which the complex made of PKC α/NF-κB p65/MAPK p38 can be
demonstrated (Fig. 6B).
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(2009, [11]), who demonstrated increased miRNA 15a levels in small
cell carcinoma. These authors showed that miRNA 15a participates in
the processing of E-cyclin, by binding to its 3′UTR. Most likely, this is
only one of several functions of this miRNA; the others still have to be
elucidated.
Currently, an opposing role for miRNA 15a has been described in
the literature for: multiple myeloma, malignant lymphoproliferative
disorders, prostate carcinoma, and pituitary adenoma (reviewed in
Aqeilan et al., [16]). It is reported by the authors that tumor cell
proliferation has been detected in parallel with low levels of miRNA
15a, seemingly making this miRNA a potential tumor suppressor. In
direct contrast, we have found high levels of miRNA 15a, correlating
with proliferating malignant tumor cell lines, representing humantumors such as renal cell carcinoma (Fig. 3A), breast carcinoma, and
malignant melanoma (Fig. 5). Our results are, however, in agreement
with the ﬁndings in small cell carcinoma (Cohen et al., 2009; [11]).
This currently unexplainable discrepancy indicates that the role of
miRNA 15a may not always be that of a tumor suppressor and
enhancer of apoptosis, but can also be associated with actively
growing malignant tumors in speciﬁc entities, necessitating further
studies to investigate this discrepancy.
Since the signal of ET-1 binding is transmitted by a speciﬁc
receptor (ETAR, [24]), its presence was investigated for all 3 cell lines
used (Fig. 6A). In addition, the ETBR could also be detected. To study
their potential role in ET-1 signaling, an experiment was conducted
analyzing the expression levels of PKC α (by Western blot) and
miRNA 15a (by qRT-PCR) with or without receptor blockage. At 24 h
after ET-1 stimulation there was an inverse relationship between
cytoplasmic PKC (higher levels as control) versus nuclear PKC
expression (lower levels as control), which was enhanced in the
cytoplasmic and nuclear compartments by ETAR blockade, and in the
cytoplasmic compartment by ETBR blockade (Fig. 7A). A highly
signiﬁcant statistical reduction in miRNA 15a levels was observed by
ETR blockade. This observation suggests that PKC α levels can be
modiﬁed by ET-receptor levels, also inﬂuencing the levels of miRNA
15a.
This suggestion is supported by studies analyzing the role of G-
proteins in ET-receptor signaling. Ligand binding to ETAR (and ETBR)
results in association with G(0), G(i)1 and G(i)2 alpha subunits [25],
while increased levels of the G(0) alpha subunit inhibit PKC. ETAR
(and ETBR) blockage should consequently lead to increased cytoplas-
mic PKC levels as shown by us in Fig. 7A. However, the intensity of the
reduction of mature miRNA 15a levels seems greater than one may
expect by the detectable levels of PKC α binding to pri-miRNA 15a in
the nucleus at 24 h. Here, additional effects of other factors such as ET-
isoforms 2, and 3 may be responsible.
In this context, it is important to remember that the ET-1 isoform
has a speciﬁc receptor afﬁnity to the ETAR, while the ETB receptor has
an equal afﬁnity to all three ET-isoforms [24]. Having demonstrated
the presence of both receptor subtypes in the cell lines studied
(Fig. 6A) and their potential inﬂuence on miRNA 15a expression, the
question arises whether the other two ET isoforms may have an
additional regulatory effect. In the literature, Karte and Davenport
[26] have demonstrated all three isoforms at the mRNA level, but only
ET-1 as a peptide. ET-2 [27] and ET-3 have been associated with
vasoconstriction and hypertension. However, reports on a possible
inﬂuence of these ET isoforms on PKC are missing. On the other hand,
ET-3 is supposed to increase the alpha G(0) subunit coupling to the
ETBR and decrease its coupling to the ETAR. This could in part explain
the observation made in Fig. 7A, where ETBR blockage leads to
increased levels of PKC α. Here, further studies are necessary to
unravel the intricate relationship between ETRs, ET-isoforms and their
inﬂuence on PKC mediated by G-coupled proteins.
In this paper, we have shown that nuclear protein PKC α levels
regulate miRNA 15a in a variety of human tumor cell lines. This
indicates that this signal pathwaymay be just as widely present as has
been shown for some of its members individually, such as NF-κB [28],
theMAPK p38 group [29], and the PKC system [30]. On the other hand,
the regulatory loop between miRNA 15a and PKC α should be studied
for each tumor type, considering opposing results between our study
and publications in the literature [17,18].
In summary, our results demonstrate that PKC α is able to form a
complex with NF-κB p65 and MAPK p38 in the cytoplasm,
transmigrating with the help of importins into the nucleus, where it
binds to pri-microRNA 15a, preventing nuclear release. However,
endothelin-1 stimulation can temporarily reduce PKC α protein
levels, leading to increased cytoplasmicmiRNA 15a levels. This system
is detectable in different tumor cell lines and may thus be relevant in
future therapeutic targeting.
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